Try our Advanced Search for more refined results
Medical Mutual of Ohio v. AbbVie Inc. et al
Case Number:
1:14-cv-08857
Court:
Nature of Suit:
385(Prop. Damage Prod. Liability)
Judge:
Firms
- Alston & Bird
- Arnold & Porter
- Baron & Budd
- Foley & Lardner
- Kanner & Whiteley
- Mayer Brown
- Morgan Lewis
- Patterson Belknap
- Reed Smith
- Simmons Hanly
Companies
- Abbott Laboratories
- AbbVie Inc.
- Allergan PLC
- Anda Inc.
- Auxilium Pharmaceuticals, Inc.
- Eli Lilly & Co.
- Endo International PLC
- Medical Mutual of Ohio
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
-
February 15, 2019
AbbVie, Eli Lilly Beat Insurer's RICO Suit in Testosterone MDL
An Illinois federal judge has entered judgment in favor of AbbVie and other makers of testosterone replacement drugs in a Racketeer Influenced and Corrupt Organizations Act suit brought by an insurer, saying there was no evidence the insurer was misled by the companies.
-
July 27, 2018
Individualized Claims Thwart Testosterone RICO MDL
An Illinois federal judge rejected a bid to certify a class of third-party payors bringing Racketeer Influenced and Corrupt Organizations Act claims against AbbVie Inc., Eli Lilly & Co. and other makers of testosterone replacement therapy products, saying the allegations are too individualized to proceed as a whole.
-
November 20, 2017
Abbvie Says Medical Mutual Being 'Cagey' In Androgel MDL
Medical Mutual of Ohio is refusing to answer AbbVie Inc.'s request for more detail on the basic premise behind its potential class action accusing AbbVie of fraudulently marketing its testosterone replacement therapy drug Androgel, the drugmaker told an Illinois federal court Monday.
-
October 04, 2017
AbbVie, Lilly Slam Discovery Bid In Testosterone MDL
AbbVie Inc. and Eli Lilly & Co. have each accused Medical Mutual of Ohio in Illinois federal court of stepping out of line by filing a premature motion to compel documents in a putative class action over fraudulently marketing testosterone replacement therapy drugs.
-
August 22, 2017
UHC Ignoring Subpoena In Testosterone MDL, Endo Says
UnitedHealthcare should hand over subpoenaed information about its dealings in testosterone replacement drugs if it wants to become part of a proposed class of insurers and third-party payors accusing drug companies of fraudulently marketing the drugs, Endo Pharmaceuticals Inc. told an Illinois federal court Monday.
-
August 30, 2016
Actavis Wants Conspiracy Claim Nixed In Testosterone MDL
Actavis on Monday asked an Illinois federal judge to reconsider letting Racketeer Influenced and Corrupt Organizations Act conspiracy charges stand in an insurer’s multidistrict litigation over fraudulent marketing for testosterone replacement drugs, arguing that the fact that Actavis entered into a promotion contract with co-defendant AbbVie Inc. doesn’t prove it knew AbbVie was allegedly engaged in illegal activity.
-
August 03, 2016
GSK, Actavis Dodge RICO Claims In Testosterone Case
An Illinois federal judge freed pharmaceutical giants GlaxoSmithKline and Actavis on Tuesday from having to face racketeering charges in a suit accusing them and other drugmakers of a fraudulent marketing scheme that led health insurers to pay for medically unnecessary testosterone replacement drugs.
-
July 11, 2016
Insurance Co. Says Testosterone Marketing Suit Must Stand
AbbVie Inc. and other drugmakers accused of running a fraudulent marketing scheme that led to health insurers' paying for medically unnecessary uses of testosterone replacement therapy drugs are demanding that the allegations against them be pled with more specificity than necessary, an insurer told an Illinois federal court Monday.
-
March 03, 2016
AbbVie, Others Say Ill. Court Misapplied 7th Circ. Precedent
AbbVie Inc. and other drugmakers accused of using fraudulent marketing that lead to health insurers paying for medically unnecessary uses of testosterone replacement therapy drugs have asked an Illinois federal judge to reconsider tossing one of two remaining claims, saying he misapplied Seventh Circuit precedent in keeping it.
-
February 04, 2016
AbbVie, Others Escape Some Testosterone Therapy Claims
An Illinois federal judge on Thursday tossed most of a putative class action accusing AbbVie Inc. and other pharmaceutical companies of causing health insurers to pay for medically unnecessary uses of testosterone replacement therapy drugs via fraudulent marketing, but allowed the deficient claims to be amended.